Cost-effectiveness analysis of the prevention of relapse of schizophrenia in the ZEUS longitudinal study Ziprasidone Extended Use in Schizphrenia (ZEUS)

Actas Espanolas de Psiquiatria

Volumn 35, Issue 4, 2007, Pages 259-262

  Bernardo, M ^a   Azanza, J R ^b   Rubio Terres C ^c   Rejas, J ^d  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c HERO Consulting   (Spain)

^d PFIZER INC   (United States)

Author keywords

Cost effectiveness; Not treating; Prevention; Schizophrenic relapse; ZEUS study; Ziprasidone

Indexed keywords

NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE; ZIPRASIDONE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DOUBLE BLIND PROCEDURE; ECONOMICS; FOLLOW UP; HUMAN; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; PIPERAZINES; RECURRENCE; SCHIZOPHRENIA; THIAZOLES;

EID: 34547266610     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Bernardo M. Redefining schizophrenia. Actas Esp Psiquiatr 2003;31:1-2.
2. Ciompi L. The effect of psychosocial factors in schizophrenia. Theoretical and practical-therapeutic consequences. Schweiz Arch Neurol Psychiatr 1995;146:207-14.
3. Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004;184:346-51.
4. Terkelsen KG, Menikoff A. Measuring the costs of schizophrenia. Implications for the post-institutional era in the US. Pharma-coeconomics 1995;8:199-222.
5. Haro JM, Salvador-Carulla L, Cavases J. Utilization of mental health services and cost of patients with schizophrenia in three areas of Spain. Brit J Psychiatry 1998;173:334-40.
6. Alvarez E, Bernardo M, Roca M. CATIE: bienvenido al mundo real. Actas Esp Psiquiatr 2006;34:213-5.
7. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353: 1209-23.
8. Peiró S, Gómez G, Navarro M. Length of stay and antipsychotic treatment costs of patients with acute psychosis admitted to hospital. Description and associated factors. The Psychosp study. Soc Psyquiatry Psychiatr Epidemiol 2004;39:507-13.
9. Bagnall AM, Lewis RA, Leitner ML. Ziprasidona para Ia esquizofrenia y la enfermedad mental severa. (Cochrane Review, translated). In: La Biblioteca Cochrane Plus, 2005, number 3. Oxford: Update Software Ltd. Available in: http://www.update-software.com. (Translated from The Cochrane Library. 2005, Issue 3. Cichester, UK: John Wiley & Sons, Ltd).
10. Arato M, O'Connor R, Meltzer HY, ZEUS Study Group. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 2002;17:207-15.
11. Rovira J, Antoñanzas F. Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation. Pharmacoeconomics 1995;8:245-52.
12. Osterheider M, Franken-Hiep K, Horn R. Total illness costs of schizophrenia and monetary evaluation of prevention of recurrence exemplified by a standard depot neuroleptic (flupenthixol decanoate). Psychiatr Prax 1998;25:38-43.